---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-050739"
form_type: "8-K"
ticker: null
cik: "0001652724"
company_name: "Lucira Health, Inc."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:45:20.686067+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lucira Health gets FDA EUA for first at-home COVID-19 & flu test; Nasdaq delisting set for March 6

## Summary
- FDA granted EUA for Lucira COVID-19 & Flu Home Test, first OTC at-home test for flu and combo COVID-19/flu.
- Test is molecular (NAAT), delivers results in 30 minutes from one nasal swab; similar performance to lab PCR.
- Nasdaq notified delisting due to Chapter 11 filing; trading suspended at opening on March 6, 2023; company will not appeal.
- Company produced inventory for autumn 2022 launch but could not bridge authorization cycle; now seeking strategic or financial partner.
- Bankruptcy court approved first-day motions on Feb 24 to continue ordinary operations during Chapter 11 case.

## SEC filing metadata
- accession: 0001193125-23-050739
- form_type: 8-K
- cik: 0001652724
- company_name: Lucira Health, Inc.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652724/000119312523050739/0001193125-23-050739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652724/000119312523050739/d455868d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-050739
- JSON: https://secwatch.observer/filing/0001193125-23-050739.json
- Plain text: https://secwatch.observer/filing/0001193125-23-050739.txt

## Key facts
- Listing & Compliance Notices
  Lucira Health, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Rules: 5101, 5110(b), IM-5101-1
  source text: February 23, 2023, the Company received written notice (the “Delisting Notice”) from the staff of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Filing and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced the Chapter 11 Filing and associated public interest concerns raised by it, concerns regarding the residual equity interest of the existing listed securities holders and co
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652724/000119312523050739/0001193125-23-050739-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.